logo

Ultragenyx Pharmaceutical Inc (RARE)



Trade RARE now with
  Date
  Headline
10/26/2018 8:03:18 AM Ultragenyx Announces Negative Topline Results From Phase 3 Study Of UX007 For Glut1 DS With Disabling Movement Disorders
10/22/2018 7:03:07 AM Ultragenyx Announces License To REGENXBIO AAV Vectors To Develop Gene Therapy For CDD
10/18/2018 8:34:38 AM Ultragenyx Announces Approval Of Mepsevii In Brazil For Treatment Of Mucopolysaccharidosis VII
9/27/2018 7:04:54 AM Ultragenyx Announces Positive Topline Cohort 2 Results From Phase 1/2 Clinical Study Of DTX301 In OTC Deficiency
9/17/2018 8:34:25 AM Ultragenyx Pharma Names Wladimir Hogenhuis COO, Effective Sept. 28
8/29/2018 8:31:10 AM Ultragenyx Announces FDA Accepts Proposal To Submit An NDA For UX007 For Long-Chain Fatty Acid Oxidation Disorders
8/6/2018 6:51:33 AM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) FY18 Rev. Estimate To 50.3 M From 40.4 M
8/6/2018 6:51:23 AM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) Q4 18 Rev. Estimate To 14.5 M From 12.1 M
8/6/2018 6:51:11 AM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) Q3 18 Rev. Estimate To 12.3 M From 10.5 M
8/6/2018 6:50:53 AM Wedbush Is Raising Ultragenyx Pharmaceutical Inc (RARE) FY18 Estimate To -4.45 From -4.48
8/6/2018 6:50:41 AM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) Q4 18 Estimate To -2.03 From -2.19
8/6/2018 6:50:24 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q3 18 Estimate To -1.99 From -0.82
8/2/2018 4:14:28 PM Ultragenyx Q2 Loss Per Share $1.06 Vs. $1.72 Last Year
7/26/2018 8:34:21 AM Ultragenyx Announces First Patient Dosed In Phase 1/2 Study Of DTX401